SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

Core Insights - SpringWorks Therapeutics, Inc. has appointed Martin Mackay, Ph.D. to its Board of Directors, bringing over 30 years of experience in pharmaceutical and biotech R&D [1][2] - Dr. Mackay's expertise in rare diseases and leadership roles at major companies like Pfizer, AstraZeneca, and Alexion will be valuable for SpringWorks as it expands its pipeline [2] - SpringWorks is focused on developing life-changing medicines for severe rare diseases and cancer, with its first FDA-approved therapy being OGSIVEO® (nirogacestat) for desmoid tumors [3] Company Overview - SpringWorks Therapeutics is a commercial-stage biopharmaceutical company that applies a precision medicine approach [3] - The company has a diversified pipeline targeting solid tumors and hematological cancers, with programs at various stages from preclinical to advanced clinical trials [3] - SpringWorks has established collaborations with industry and academic innovators to enhance its portfolio and create more solutions for patients [3] Leadership and Experience - Dr. Mackay is a co-founder and Executive Chairman of Rallybio, a clinical-stage biotechnology company focused on severe rare diseases [2] - His previous roles include Executive Vice President at Alexion and President of R&D at AstraZeneca, where he led global R&D functions [2] - Dr. Mackay has held various positions at Pfizer, including Senior Vice President of Worldwide Development, contributing to a wide range of investigational medicines [2] Educational Background - Dr. Mackay holds a First-Class Honours Degree in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University of Edinburgh [2]